222 related articles for article (PubMed ID: 35661004)
1. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
3. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
4. The N6-Methylandenosine-Related Gene
Jiang X; Shi Y; Chen X; Xu H; Huang X; Li L; Pu J
Front Mol Biosci; 2022; 9():773662. PubMed ID: 35309512
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.
Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C
Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303
[TBL] [Abstract][Full Text] [Related]
6. NCAPG as a Novel Prognostic Biomarker in Glioma.
Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
Front Oncol; 2022; 12():831438. PubMed ID: 35280743
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation-regulated SNX20 overexpression correlates with poor prognosis, immune cell infiltration, and low-grade glioma progression.
Chen X; Jiang X; Wang H; Wang C; Wang C; Pan C; Zhou F; Tian J; Niu X; Nie Z; Chen W; Huang X; Pu J; Li C
Aging (Albany NY); 2022 Jun; 14(12):5211-5222. PubMed ID: 35771139
[TBL] [Abstract][Full Text] [Related]
8. YTHDF2 correlates with tumor immune infiltrates in lower-grade glioma.
Lin X; Wang Z; Yang G; Wen G; Zhang H
Aging (Albany NY); 2020 Sep; 12(18):18476-18500. PubMed ID: 32986017
[TBL] [Abstract][Full Text] [Related]
9. LncRNA RP3-525N10.2-NFKB1-PROS1 triplet-mediated low PROS1 expression is an onco-immunological biomarker in low-grade gliomas: a pan-cancer analysis with experimental verification.
Zhou Y; Xiao D; Jiang X
J Transl Med; 2022 Jul; 20(1):335. PubMed ID: 35879775
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis regarding the correlation between GAS2 family genes and human glioma prognosis.
Zhao C; Zhang N; Cui X; Zhang X; Ren Y; Su C; He J; Zhang W; Sun X; Yang J; Gao X
Cancer Med; 2021 Apr; 10(8):2826-2839. PubMed ID: 33713047
[TBL] [Abstract][Full Text] [Related]
11. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
12. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
Li J; Wang J; Ding Y; Zhao J; Wang W
BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511
[TBL] [Abstract][Full Text] [Related]
13. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
14.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of RAB34 associates with tumor aggressiveness and immune infiltration in glioma.
Hou P; Wan Q; Wang Q; Wu X; Lu X
Biosci Rep; 2022 Oct; 42(10):. PubMed ID: 36222286
[TBL] [Abstract][Full Text] [Related]
16. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
17. MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway.
Ren J; Zheng S; Zhang L; Liu J; Cao H; Wu S; Xu Y; Sun J
Cancer Med; 2023 May; 12(10):11624-11640. PubMed ID: 36999945
[TBL] [Abstract][Full Text] [Related]
18. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
19. Expression and Prognostic Role of PANK1 in Glioma.
Zhao Z; Xu X; Ma S; Li L
Comb Chem High Throughput Screen; 2024; 27(5):715-724. PubMed ID: 37138430
[TBL] [Abstract][Full Text] [Related]
20. The RPL4P4 Pseudogene Is a Prognostic Biomarker and Is Associated with Immune Infiltration in Glioma.
Wang Z; Aili Y; Wang Y; Maimaitiming N; Qin H; Ji W; Fan G; Li B
Oxid Med Cell Longev; 2022; 2022():7967722. PubMed ID: 35993018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
